Leishmania mexicana is able to interact with the fibrinolytic system through its component plasminogen, the zymogenic form of the protease plasmin. In this study a new plasminogen binding protein of this parasite was identified: LACK, the Leishmania homolog of receptors for activated C-kinase. Plasminogen binds recombinant LACK with a K(d) value of 1.6±0.4 μM, and binding is lysine-dependent si...

objective: development of high producing mammalian cell lines is a major bottleneck in manufacturing of recombinant therapeutic proteins. this study examines the effect of using the matrix attachment region from the human interferon beta gene in combination with promoter activation strategy with e1a 13s protein on human tissue plasminogen activator (t-pa) expression in chinese hamster ovary (ch...

Current treatment for acute ischemic stroke aims at recanalizing the occluded blood vessel to reperfuse brain tissue. Clot removal can be achieved pharmacologically with a thrombolytic drug, such as recombinant tissue plasminogen activator, or mechanical thrombectomy. However, reopening does not guarantee full reperfusion, which has been referred reperfusion failure. When it occurs, failure sig...

IED20006 THE FIRST clinical report of the use of a thrombolytic agent (streptokinase) to treat acute pulmonary embolism (PE) appeared in 1964,1 and the first randomized clinical trial comparing urokinase plus heparin with heparin alone was published in 1970.2 A randomized clinical trial comparing urokinase to streptokinase in the treatment of PE was published in 1974.3 The first report of a thi...

in the neuroscience intensive care unit at the University of Virginia Health System in Charlottesville. properties of the fibrinolytic agent and the impact of adjuvant therapies such as antiplatelet and anticoagulant agents must also be considered. Tenecteplase is a variant of tissue plasminogen activator (t-PA) that is genetically engineered to have increased fibrin specificity, a longer half-...

conclusions due to considerable inter- and intra- heterogeneity among studies performed by other centers such as differences in study project, background, and population features, determining a pharmacotherapy model based on safe implementation of treatments in stroke or sits seem advantageous. results age, time of onset, systolic blood pressure, diabetes, stroke severity, co-morbidities and pr...

Background and Purpose—Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C improves outcomes; however, activated protein C also has bleeding side effects. In contrast, activation of endogenous protein C using thrombin mutant W215A/E...

Endostatin, a M(r) 20,000 fragment of collagen XVIII, is able to inhibit angiogenesis and induce apoptosis in endothelial cells in vivo. We analyzed the effectsof recombinant endostatin on human microvascular endothelial cells, focusing on pericellular plasminogen activation and its targeting by the focal adhesion-associated cytoskeletal structures. Analysis of the proteolytic plasminogen activ...

BACKGROUND AND PURPOSE Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C improves outcomes; however, activated protein C also has bleeding side effects. In contrast, activation of endogenous protein C using thrombin mutant W215A/E...